Toscana Biomarkers
italiano english
Toscana Biomarkers è un'azienda strat-up residente all'interno del bio-incubator della Fondazione Toscana Life Sciences
Toscana Biomarkers Srl
Via Fiorentina 1
I-53100 Siena, Italy
Phone: +39 0577 231271/2
Fax: +39 0577 274107
Capitale Sociale euro 100.000,00 i.v.
Registro d'impresa di Siena, C.F.
e P.IVA 02042930970
R.E.A. Siena 128830
info@toscanabiomarkers.com
Via Fiorentina 1
I-53100 Siena, Italy
Phone: +39 0577 231271/2
Fax: +39 0577 274107
Capitale Sociale euro 100.000,00 i.v.
Registro d'impresa di Siena, C.F.
e P.IVA 02042930970
R.E.A. Siena 128830
info@toscanabiomarkers.com
RA
Rheumatoid Arthritis (RA) is the most common autoimmune disease in humans and is characterized by inflammation of synovial membranes that can lead to destruction of synovial joints. RA is diagnosed primarily on clinical manifestations. Serological supporting evidence has long been restricted to the determination of IgM anti-rheumatoid factor. However, these antibodies frequently occur in many inflammatory diseases and in healthy elderly individuals.Several post-translational modifications of proteins (such as deimination, methylation, hydroxylation and glycosylation) have been associated with RA pathogenesis leading to the identification of differently modified autoantigens (1). Sensitive and specific diagnostic assays are based on the detection of anti-citrullinated peptide antibodies in RA patients (2-4).
In this scenario, Toscana Biomarkers in cooperation with the Clinical Immunology Unit of the University of Pisa (Italy) is working on the sensitivity optimization of ELISA based on citrullinated peptide.
References
1) Doyle H.A. and Mamula M.J., Trends Immunol. 22, 443-449 (2001).
2) Girbal-Neuhauser E. et al., J. Immunol. 162, 585-594 (1999).
3) Vossenaar E.R. and van Venrooij W.J., Clin. Appl. Immunol. Rev. 4, 239-262 (2004).
4) van Gaalen F.A. et al., Ann. Rheum. Dis. 64, 1510-1512 (2005).
